Romiplostim for secondary thrombocytopenia following allogeneic stem cell transplantation in children

Natalia Maximova, D. Zanon, F. Rovere, A. Maestro, G. Schillani, R. Paparazzo

Research output: Contribution to journalArticle

Abstract

The outcome of romiplostim for secondary failure of platelet recovery (SFPR) was investigated in children who had undergone hematopoietic stem cell transplantation (HSCT). Seven transfusion-dependent pediatric patients (median age 11 years), with platelet counts below 10 × 109/L, received four weekly doses of subcutaneous romiplostim to treat SFPR developed after HSCT. All patients, except one (patient 4), became platelet transfusion-independent in the second week from the beginning of treatment and no patient needed to discontinue drug treatment because of adverse events. Romiplostim could represent a beneficial first-line treatment, but further studies are required.

Original languageEnglish
Pages (from-to)626-632
Number of pages7
JournalInternational Journal of Hematology
Volume102
Issue number5
DOIs
Publication statusPublished - Nov 1 2015

Keywords

  • Pediatric patients
  • Romiplostim
  • Secondary failure of platelet recovery
  • Virus infection

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Romiplostim for secondary thrombocytopenia following allogeneic stem cell transplantation in children'. Together they form a unique fingerprint.

  • Cite this